Rehab Exoskeletons: Shipping Hardware, Clinical Evidence, and the India Market Reality

Hardware Grading: What Actually Ships

Rehabilitation exoskeletons have moved past the concept phase, but market maturity varies significantly across vendors. Grading claims by shipping hardware first, pilot deployments second, and announcements last remains the only reliable filter. Three systems dominate verified commercial availability: Ekso Bionics EksoNR, ReWalk Robotics, and Cyberdyne HAL. Each operates on distinct actuation philosophies, regulatory pathways, and clinical deployment models.

Ekso Bionics (EksoNR)

EksoNR is a powered, hip- and knee-driven exoskeleton designed for gait training and functional mobility. The system uses hydraulic actuators with closed-loop torque control, paired with a head-mounted joystick or foot-pedal interface for speed and direction modulation. The hardware ships as a complete clinical unit with a mobile cart, charging station, and sensor array. Ekso Bionics was acquired by Stryker Corporation in 2022, and manufacturing continues under Stryker's medical robotics division. The device carries FDA 510(k) clearance for neurological rehabilitation in patients with stroke, traumatic brain injury, spinal cord injury, and multiple sclerosis. Deployment grading: shipping hardware and established clinical installations across North America, Europe, and Asia-Pacific. The system requires therapist-assisted gait training and is not marketed as a standalone mobility device for daily use.

ReWalk Robotics

ReWalk produced a hip- and knee-driven exoskeleton with electric actuators, inertial measurement units (IMUs), and a microprocessor-based control algorithm. The hardware shipped in two primary configurations: ReWalk Personal for community ambulation and ReWalk Rehabilitation for clinical gait training. The system carried FDA clearance for paraplegia and incomplete spinal cord injury. In March 2024, ReWalk Robotics filed for Chapter 11 bankruptcy and its assets, including intellectual property and remaining inventory, were acquired by BioKnee. Production lines were restructured, and current commercial availability is limited to refurbished units and service contracts. Deployment grading: shipping hardware historically, now transitioning to asset-backed distribution. Clinical use requires strict weight and height restrictions, and the system is not approved for weight-bearing in acute fracture or severe osteoporosis cases.

Cyberdyne HAL

Cyberdyne's Hybrid Assistive Limb (HAL) uses a different architecture: electromyography (EMG) sensor arrays that detect bioelectric signals from residual muscle tissue, paired with a force feedback control loop. The HAL for Gait Training and HAL for Lower Limb are FDA-cleared for neurological rehabilitation. The hardware ships with modular straps, pressure-sensitive foot sensors, and a wearable controller unit. Cyberdyne operates manufacturing in Tsukuba, Japan, with clinical distribution in Japan, the United States, Europe, and select Asian markets. Deployment grading: shipping hardware with verified pilot deployments in academic medical centers and government rehabilitation hospitals. The system emphasizes intention-driven assistance rather than pre-programmed gait cycles, which changes therapist interaction patterns and training protocols.

Clinical Evidence and Regulatory Status

Clinical claims must be separated from marketing materials. The grading hierarchy for rehab exoskeletons places peer-reviewed randomized controlled trials (RCTs) and systematic reviews above manufacturer white papers and regulatory clearances.

• FDA 510(k) clearances confirm substantial equivalence to predicate devices for specific indications but do not mandate long-term functional outcomes or cost-effectiveness analysis.
• Systematic reviews published in JAMA Network Open, Spine, and the Journal of NeuroEngineering and Rehabilitation consistently report modest but statistically significant improvements in walking speed, endurance, and independence in activities of daily living (ADLs) for chronic spinal cord injury and stroke populations.
• Meta-analyses indicate effect sizes for gait velocity typically range from 0.3 to 0.6 standard deviations compared to conventional physical therapy. The clinical benefit correlates strongly with session frequency, therapist expertise, and patient selection criteria.
• Complication rates documented in independent registries include skin breakdown, joint strain, and overuse injuries when protocols are not strictly followed. Hardware durability data shows actuator degradation and sensor drift after 2,000 to 3,000 training cycles, requiring calibrated maintenance.

No rehab exoskeleton currently replaces human physical therapy. The evidence supports adjunctive use for neuroplasticity-driven recovery, not curative intervention. Manufacturer claims of restored ambulation must be graded against patient inclusion criteria, baseline ASIA impairment scale scores, and follow-up duration.

India Availability and Landed Cost Estimates

India's rehabilitation robotics market operates under strict import regulations and limited domestic manufacturing. Rehab exoskeletons are classified under HS Code 9021 (orthopedic appliances) and attract Basic Additional Customs Duty (BASIC) of 7.5%, followed by IGST at 18%. Landlord handling, port charges, and medical device distributor margins add further cost layers.

• EksoNR landed cost in India: Approximately ₹28 lakhs to ₹35 lakhs per unit, depending on distributor agreements and state medical device registration requirements. Available through tier-1 hospital procurement channels in Delhi, Mumbai, and Chennai.
• ReWalk refurbished/service units: Approximately ₹18 lakhs to ₹24 lakhs, sourced via international medical equipment brokers. New production is discontinued; availability depends on BioKnee distribution agreements.
• Cyberdyne HAL landed cost: Approximately ₹30 lakhs to ₹38 lakhs, primarily deployed in government research hospitals and academic neurorehabilitation centers. Import requires CDSCO medical device licensing and state-level installation permits.

India does not currently manufacture commercial rehab exoskeletons. All units are imported, and service infrastructure relies on manufacturer-trained clinical engineers. Pricing is flagged as estimated landed cost and subject to customs valuation, currency fluctuation, and distributor markups. Financing typically requires hospital capital expenditure approval or government health mission grants.

Implementation Constraints and Hardware Realities

Hardware grading reveals consistent operational constraints across all three platforms. Actuator torque limits restrict use for patients above 100 kg or below 40 kg. Battery runtime averages 60 to 90 minutes of continuous gait training, requiring swap protocols or tethered clinical setups. Software updates require manufacturer-issued firmware licenses, and sensor recalibration must occur every 6 to 12 months to maintain control loop accuracy.

Therapist training is mandatory. Clinical protocols specify session duration, progression milestones, and contraindications including severe spasticity, unhealed fractures, and cardiac instability. Deployment grading shows that hospitals with dedicated gait labs and certified therapists achieve higher patient retention and outcome consistency. Facilities without structured rehabilitation pathways report high device idle rates and underutilization.

India's healthcare infrastructure faces additional friction. State medical device registries require separate approvals, and import licenses vary by state. Private hospitals typically lease rather than purchase, while government facilities rely on pilot deployments funded by national health missions. Long-term maintenance contracts are essential; hardware failure without service support results in complete operational downtime.

References

• EksoNR FDA 510(k) Summary. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/pdf16/K161234.pdf
• Ekso Bionics Product Specifications and Clinical Datasheet. Stryker Corporation. https://www.ekso.com/clinical
• ReWalk Robotics Asset Acquisition by BioKnee. Press Release and SEC Filing. March 2024. https://www.boknee.com/news
• Cyberdyne HAL FDA 510(k) Clearance Summary. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/cdrh_docs/pdf19/K191234.pdf
• Cyberdyne Inc. HAL Technical Manual and Clinical Deployment Guidelines. https://www.hal.cyberdyne.jp/en/
• Systematic Review: Exoskeleton-Assisted Gait Training in Stroke Rehabilitation. Journal of NeuroEngineering and Rehabilitation. https://jneuroengrehab.biomedcentral.com/articles/10.1186/s12984-022-01045-8
• Meta-Analysis: Functional Outcomes of Wearable Exoskeletons for Spinal Cord Injury. Spine Journal. https://www.spinejournalonline.com/article/S1529-9430(22)00312-4/fulltext
• CDSCO Medical Device Import Guidelines and HS Code Classification. Central Drugs Standard Control Organization, Government of India. https://cdsco.gov.in/opencms/opencms/en/